High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
复制标题
DOI：
10.1093/jrr/rrt128
复制
发表时间：
2014-05
影响因子：
2
通讯作者：
Hayakawa K
中科院分区：
文献类型：
--
作者：
Ishiyama H;Satoh T;Kitano M;Tabata K;Komori S;Ikeda M;Soda I;Kurosaka S;Sekiguchi A;Kimura M;Kawakami S;Iwamura M;Hayakawa K
本研究的目的是报告高剂量率（HDR）近距离放射治疗和大分割外照射放疗（EBRT）联合长期雄激素剥夺治疗（ADT）治疗国家综合癌症网络（NCCN）标准定义的高危（HR）和极高危（VHR）前列腺癌的结局。回顾性分析了2003年至2008年间接受192 Ir-HDR近距离放射治疗和大分割EBRT联合长期ADT的178例HR（n = 96，54%）和VHR（n = 82，46%）前列腺癌患者的数据。90%计划靶体积的平均剂量为6.3戈伊/次HDR近距离放射治疗。5次HDR治疗后，给予10次3戈伊的EBRT。所有患者最初均接受了≥6个月的新辅助ADT，EBRT后辅助ADT持续36个月。从放疗开始，中位随访时间为61个月（范围：25-94个月）。5年生化无疾病证据、无临床失败和总生存率分别为90.6%（HR，97.8%; VHR，81.9%）、95.2%（HR，97.7%; VHR，92.1%）和96.9%（HR，100%; VHR，93.3%）。放射治疗肿瘤学组定义的最高晚期泌尿生殖系统毒性为2级（7.3%的患者）和3级（9.6%的患者）。最高晚期胃肠道毒性为2级（2.8%的患者）和3级（0%）。虽然这种三种方式的方法的5年结果似乎是有利的，进一步的随访是必要的，以验证这种密集的方法相比，标准EBRT方法的临床和生存优势。
The purpose of this study was to report the outcomes of high-dose-rate (HDR) brachytherapy and hypofractionated external beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) for National Comprehensive Cancer Network (NCCN) criteria-defined high-risk (HR) and very high-risk (VHR) prostate cancer. Data from 178 HR (n = 96, 54%) and VHR (n = 82, 46%) prostate cancer patients who underwent 192Ir-HDR brachytherapy and hypofractionated EBRT with long-term ADT between 2003 and 2008 were retrospectively analyzed. The mean dose to 90% of the planning target volume was 6.3 Gy/fraction of HDR brachytherapy. After five fractions of HDR treatment, EBRT with 10 fractions of 3 Gy was administered. All patients initially underwent ≥6 months of neoadjuvant ADT, and adjuvant ADT was continued for 36 months after EBRT. The median follow-up was 61 months (range, 25–94 months) from the start of radiotherapy. The 5-year biochemical non-evidence of disease, freedom from clinical failure and overall survival rates were 90.6% (HR, 97.8%; VHR, 81.9%), 95.2% (HR, 97.7%; VHR, 92.1%), and 96.9% (HR, 100%; VHR, 93.3%), respectively. The highest Radiation Therapy Oncology Group-defined late genitourinary toxicities were Grade 2 in 7.3% of patients and Grade 3 in 9.6%. The highest late gastrointestinal toxicities were Grade 2 in 2.8% of patients and Grade 3 in 0%. Although the 5-year outcome of this tri-modality approach seems favorable, further follow-up is necessary to validate clinical and survival advantages of this intensive approach compared with the standard EBRT approach.
登录
查看更多内容
影响因子：
1.9
作者：
Agoston, Peter;Major, Tibor;Polgar, Csaba
通讯作者：
Polgar, Csaba
DOI：
10.1259/bjr/15403217
发表时间：
2012-11-01
期刊：
The British journal of radiology
影响因子：
--
作者：
Challapalli, A;Jones, E;Mangar, S A
通讯作者：
Mangar, S A
影响因子：
3.3
作者：
Mitsumori, Michihide;Sasaki, Yoshihide;Ogawa, Osamu
通讯作者：
Ogawa, Osamu
影响因子：
6.6
作者：
Phan, Thinh P.;Syed, A. M. Nisar;Khan, Farhan
通讯作者：
Khan, Farhan
DOI：
10.1016/j.ijrobp.2012.07.006
发表时间：
2013-03-01
影响因子：
7
作者：
Khor, Richard;Duchesne, Gillian;Williams, Scott
通讯作者：
Williams, Scott